【摘要】 目的 :观察肉碱复方制剂对急性冠脉综合征 (ACS)患者氧自由基的影响 ,评价该制剂在 ACS治疗中的临床价值。方法 :急性冠脉综合征患者共 4 0例 ,随机分为治疗组 (A组 ,2 0例 ) ,口服肉碱复方制剂 1 0 m L,每日 2次 ,连续 30 d,余同 B组 ;对照组 (B组 ,2 0例 )常规治疗 ;C组为正常献血者。测定 A、 B两组治疗前后血清 SOD、MDA含量等相关指标。结果 :血清 SOD:A组治疗前和 B组治疗前后均低于 C组 (P<0 .0 1 ) ,A组治疗后与 C组比较差异无显著性 ;治疗前 A、B组差异无显著性 (P>0 .0 5 ) ,治疗后 A组高于 B组 ;A组治疗后高于治疗前 (P<0 .0 1 ) ,B组治疗前后无变化。血清 MDA:A和 B组治疗前后均高于 C组 (P<0 .0 1 ) ;治疗前和治疗后 A和 B组比较差异无显著性 (P>0 .0 5 ) ;A和 B组治疗后低于治疗前 (P<0 .0 1 ) ,但仍于高 C组。结论 :肉碱复方制剂可以减轻氧自由基的损伤作用 ,保护急性冠脉综合征患者缺血心肌更多还原

【Abstract】 Objective To observe the effects of complex pharmaceutics containing carnitine and eortcd on oxygen free radical (OFR) activity in acute coronary syndrome (ACS) patients. Methods Forty patients with ACS were divided into two groups randomly:carnitine and eortcd therapy group (A group, 20 cases) and routine therapy group (B group ,20 cases). 20 healthy blood donors were served as control (C group).Patients in A group were given carnitine and eortcd 10 mL ,bid p o., twice a day for 30 days, and other administrations were the same as B group. The levels of serum SOD and MDA in A and B group before and after therapy were detected.Results The levels of serum SOD in A group before therapy and B group before and after therapy were lower than that in C group ( P <0 01),there was no diffence between A group after therapy and C group, as well as A and B group before therapy ( P >0 05) . After therapy, A group was higher than B group. The concentration of MDA in A and B groups were higher than that in C group ( P <0 01).The level of serum SOD in A group increased significantly after therapy ( P <0 05), there was no significant difference in B group before and after therapy ( P <0 05); the MDA in A and B groups decreased markedly after therapy, compared with C group ( P >0 01), before and after therapy, there was no significant difference between A and B group ( P >0 05). The levels of serum MDA after therapy in A and B group were lower than before therapy ( P <0 01), however, they were higher than C group. Conclusion Canitine and eortcd can alleviate the injury of OFR and has protective function on ischemic myocardium in ACS patients.更多还原